Page last updated: 2024-11-04

benserazide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2327
CHEMBL ID1096979
CHEBI ID64187
SCHEMBL ID34522
SCHEMBL ID20509005
MeSH IDM0002315

Synonyms (101)

Synonym
ro 44602
dl-serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide
benserazide [usan:inn:ban]
dl-seryltrihydroxybenzylhydrazine
benserazida [inn-spanish]
dl-serine 2-(2,3,4-trihydroxybenzyl)hydrazide
brn 3984490
serine, 2-(2,3,4-trihydroxybenzyl)hyrazide, dl-
ro 4-4602
benserazidum [inn-latin]
dl-serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide
serazide
AB00053423-14
AB00053423-13
DIVK1C_000469
KBIO1_000469
2-amino-3-hydroxy-n'-(2,3,4-trihydroxybenzyl)propanohydrazide
benserazide (usan/inn)
322-35-0
D03082
SPECTRUM_000070
BSPBIO_000876
LOPAC0_000233
PRESTWICK3_000938
BSPBIO_001904
AB00053423
benserazide
BPBIO1_000964
KBIOGR_000654
KBIO2_003038
KBIO2_005606
KBIOSS_000470
KBIO2_000470
KBIO3_001404
NINDS_000469
PRESTWICK0_000938
SPBIO_000220
SPECTRUM2_000140
SPECTRUM4_000247
SPBIO_003045
PRESTWICK1_000938
SPECTRUM3_000312
IDI1_000469
SPECTRUM5_000856
PRESTWICK2_000938
NCGC00089783-02
HMS2089P07
AC-12038
NCGC00015163-06
BRD-A61194565-003-14-8
benserazide (as hydrochloride)
chebi:64187 ,
CHEMBL1096979
ro-4-4602
2-amino-3-hydroxy-n'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide
benserazidum
benserazida
unii-762os3zeju
762os3zeju ,
benseraszide
CCG-204328
AKOS015960744
NCGC00015163-03
NCGC00015163-04
FT-0622614
NCGC00015163-08
dl-serine 2-[(2,3,4-trihydroxyphenyl)methyl]hydrazide
2-amino-3-hydroxy-n'-(2,3,4-trihydroxybenzyl)propanehydrazide
benserazide [who-dd]
madopar component benserazide
benserazide [usan]
prolopa component benserazide
benserazide [inn]
benserazide [mart.]
benserazide [mi]
gtpl5150
STL483707
2-amino-3-hydroxy-n'-(2,3,4-trihydroxybenzyl)propanehydrazide (non-preferred name)
SCHEMBL34522
dl-seryl 2,3,4-trihydroxybenzylhydrazine
component of madopa
2-amino-3-hydroxy-n'-(2,3,4-trihydroxybenzyl)propanohydrazide #
BNQDCRGUHNALGH-UHFFFAOYSA-N
serine, 2-(2,3,4-trihydroxybenzyl)hydrazide, dl-
benserazid a
bdbm49122
2-azanyl-3-oxidanyl-n''-[[2,3,4-tris(oxidanyl)phenyl]methyl]propanehydrazide;hydrochloride
2-amino-3-hydroxy-n''-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide;hydrochloride
cid_26964
2-amino-3-hydroxy-n''-(2,3,4-trihydroxybenzyl)propionohydrazide;hydrochloride
AB00053423_16
AB00053423_15
DTXSID9022651
SBI-0050221.P004
DB12783
2-amino-3-hydroxy-2'-(2,3,4-trihydroxybenzyl)propanohydrazide
SCHEMBL20509005
Q818165
SDCCGSBI-0050221.P005
NCGC00015163-17
EN300-26189428

Research Excerpts

Overview

Benserazide is an irreversible inhibitor of peripheral aromatic L-amino acid decarboxylase that prevents the breakdown of levodopa in the bloodstream.

ExcerptReferenceRelevance
"Benserazide is an irreversible inhibitor of peripheral aromatic L-amino acid decarboxylase that prevents the breakdown of levodopa in the bloodstream."( Nanocarrier for levodopa Parkinson therapeutic drug; comprehensive benserazide analysis.
Etminan, N; Rahmanifar, E; Yoosefian, M, 2018
)
1.44
"Benserazide was found to be a noncompetitive inhibitor."( Characteristics and specificity of phenelzine and benserazide as inhibitors of benzylamine oxidase and monoamine oxidase.
Andree, TH; Clarke, DE, 1982
)
1.24

Effects

Benserazide has been used chronically to inhibit amino acid decarboxylase to enhance plasma levels of L-dopa. Benserazid has been approved for 50 years in Europe and Canada for Parkinson's disease treatment.

ExcerptReferenceRelevance
"Benserazide has a relatively benign safety profile having been approved for 50 years in Europe and Canada for Parkinson's disease treatment."( Benserazide racemate and enantiomers induce fetal globin gene expression in vivo: Studies to guide clinical development for beta thalassemia and sickle cell disease.
Alimardanov, A; Faller, A; Haugabook, SJ; Huang, J; Li, B; Makala, L; Pace, BS; Perrine, S; Sangerman, J; Takezaki, M; Tawa, GJ; Toney, L; Wang, A; Wolf, RF; Xu, H; Xu, X; Zheng, W, 2021
)
2.79
"Benserazide has a relatively benign safety profile having been approved for 50 years in Europe and Canada for Parkinson's disease treatment."( Benserazide racemate and enantiomers induce fetal globin gene expression in vivo: Studies to guide clinical development for beta thalassemia and sickle cell disease.
Alimardanov, A; Faller, A; Haugabook, SJ; Huang, J; Li, B; Makala, L; Pace, BS; Perrine, S; Sangerman, J; Takezaki, M; Tawa, GJ; Toney, L; Wang, A; Wolf, RF; Xu, H; Xu, X; Zheng, W, 2021
)
2.79
"Benserazide has been used chronically to inhibit amino acid decarboxylase to enhance plasma levels of L-dopa."( Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice.
Boosalis, MS; Dai, Y; Faller, DV; Li, B; Makala, LH; Nouraie, M; Pace, BS; Perrine, SP; Sangerman, JI; Shen, L; White, E; White, GL; Wolf, RF, 2015
)
1.14

Actions

Benserazide was shown to activate HBG gene transcription in a high throughput screen, and subsequent studies confirmed fetal hemoglobin (HbF) induction in erythroid progenitors from hemoglobinopathy patients.

ExcerptReferenceRelevance
"Benserazide was shown to activate HBG gene transcription in a high throughput screen, and subsequent studies confirmed fetal hemoglobin (HbF) induction in erythroid progenitors from hemoglobinopathy patients, transgenic mice containing the entire human β-globin gene (β-YAC) and anemic baboons."( Benserazide racemate and enantiomers induce fetal globin gene expression in vivo: Studies to guide clinical development for beta thalassemia and sickle cell disease.
Alimardanov, A; Faller, A; Haugabook, SJ; Huang, J; Li, B; Makala, L; Pace, BS; Perrine, S; Sangerman, J; Takezaki, M; Tawa, GJ; Toney, L; Wang, A; Wolf, RF; Xu, H; Xu, X; Zheng, W, 2021
)
2.79
"Benserazide induces an increase of serum prolactin in man, possibly as the result of an impairment of the dopamine effect on the pituitary and/or on the outer median eminence caused by the inhibition on L-dopa decarboxylase. "( Lack of counteracting effect of liposomes on benserazide-induced hyperprolactinemia.
Carolei, A; Masturzo, P; Murialdo, G; Polleri, A; Toffano, G, 1979
)
1.96

Treatment

Pretreatment with benserazide for up to 3h did not alter the motor response to L-DOPA compared to simultaneous administration with L- DOPA. Pretreatment with l-Dopa (50 mg/kg i.p.) either lessened or completely suppressed any sign of sympathetic stimulation.

ExcerptReferenceRelevance
"Benserazide treatment perturbed the kinetochore and microtubule interaction and inhibited the proliferation of HeLa cells with an IC50 of 101 μM with a mitotic block of 12 %."( Benserazide Perturbs Kif15-kinesin Binding Protein Interaction with Prolonged Metaphase and Defects in Chromosomal Congression: A Study Based on in silico Modeling and Cell Culture.
Rathinasamy, K; Sebastian, J, 2020
)
2.72
"Benserazide treatment caused a large reduction in the noradrenaline content of the cerebral cortex throughout 24 hr."( Differential effect of benserazide on catecholamine concentrations in the rat pineal, cerebral cortex and hypothalamus.
Ho, AK; Smith, JA, 1983
)
1.3
"In benserazide-pretreated DR and DS, sodium excretion during VE was similar, but only 50-51% of that in the respective vehicle-treated group."( In vivo evidence for a defect in the dopamine DA1 receptor in the prehypertensive Dahl salt-sensitive rat.
Hansell, P,
)
0.65
"Benserazide treatment produced no significant change in brain 5-HT content."( The effects of a decarboxylase inhibitor, benserazide, on both thermoregulation and chlorpromazine-induced hypothermia in rats.
Chern, YF; Chow, CF; Lin, MT, 1978
)
1.24
"5. Benserazide treatment inhibited platelet MAO activity in certain subjects."( Intravenous L-5-hydroxytryptophan in normal subjects: an interdisciplinary precursor loading study. Part III: Neuroendocrinological and biochemical changes.
Gastpar, M; Graw, P; Lacoste, V; Pühringer, W; Wirz-Justice, A, 1976
)
0.77
"Pre-treatment with benserazide for up to 3h did not alter the motor response to L-DOPA compared to simultaneous administration with L-DOPA."( The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
Fisher, R; Jackson, MJ; Jenner, P; Rose, S; Tayarani-Binazir, KA; Zoubiane, G, 2010
)
0.68
"Pretreatment by benserazide (50 mg/kg) and L.dopa (100 mg/kg) reduces functionnal deficiency produced by hypoxic hypoxia in rats reduces hemodynamic modifications in relation to it (rheoencephalogram) without any effect on ventilation."( [Effect of L-dopa combined with benserazide on hemodynamics and motor activity in hypoxic rats].
Belliard, JP; Boismare, F; Hacpille, L; Le Poncin, M, 1975
)
0.88
"Pretreatment with benserazide (20 mg/kg i.v.) and L-Dopa (50 mg/kg i.p.) either lessened or completely suppressed any sign of sympathetic stimulation."( Cardiovascular responses to acute hypoxia in dogs pretreated with benserazide and L-DOPA.
Boismare, F; Hacpille, L; Le Poncin, M, 1976
)
0.82
"Pretreatment by benserazide (50 mg/kg i.p.) and L-Dopa (100 mg/kg i.p.) in rats induces a reduction of the diminution of motility after hypoxia and a stabilization of cerebral blood flow during and after hypoxia. "( Reduction of hypoxia-induced disturbances by previous treatment with benserazide and L-dopa in rats.
Belliard, JP; Boismare, F; Hacpille, L; le Poncin, M, 1975
)
0.83
"pretreatment with benserazide, a peripheral decarboxylase inhibitor, in both serum and brain."( Effect of L-threo-3,4-dihydroxyphenylserine(L-threo-DOPS) on brain and serum MHPG levels in mice: evidence for NE formation in CNS.
Karai, N; Kato, T; Katsube, J; Katsuyama, M; Nakamura, M, 1987
)
0.6

Toxicity

ExcerptReferenceRelevance
" The adverse effect reappeared in a more severe and prolonged form when she was treated one year later with levodopa in combination with the peripheral decarboxylase inhibitor Ro-4-4602."( Prolonged symptoms of brain dysfunction--adverse effect of levodopa.
Anggård, E; Samuelsson, K, 1976
)
0.26
" L-DOPA pretreatment did not significantly alter any of the toxic effects of the amphetamine."( Neurotoxic effects of amphetamine plus L-DOPA.
Halladay, AK; Myers, CS; Wagner, GC; Widmer, DA, 1999
)
0.3
" Adverse effects from Western drug-based medical intervention prevent long-term adherence to these therapies in many patients."( Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: study protocol of a multicenter, open-label, randomized active-controlled trial.
Ma, YZ; Shen, XM; Zhang, J, 2013
)
0.39
" The Unified Parkinson's Disease Rating Scale scores, TCM symptoms scores, quality of life, change of Madopar's dosage and the toxic and adverse effects of Madopar will be observed during a 3-month treatment period and through a further 6-month follow-up period."( Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: study protocol of a multicenter, open-label, randomized active-controlled trial.
Ma, YZ; Shen, XM; Zhang, J, 2013
)
0.39
" Reported adverse events were comparable between LB and LC users."( Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Kuoppamäki, M; Leinonen, M; Poewe, W, 2015
)
0.65
" In the safety evaluation, it was found that acupuncture combined with Madopar was associated with significantly fewer adverse effects including gastrointestinal reactions (RR=0."( Effectiveness and safety of acupuncture combined with Madopar for Parkinson's disease: a systematic review with meta-analysis.
Chen, L; Chen, W; Dong, H; Geng, G; Li, T; Liu, H; Zhan, S; Zhang, Z, 2017
)
0.46

Pharmacokinetics

The validated method was applied in a pharmacokinetic study with a levodopa/benserazide tablet formulation in healthy volunteers. Half-life and bioavailability increased approximately 2-fold compared with placebo. Maximum plasma concentration (Cmax) and time to Cmax (tmax) were unaffected.

ExcerptReferenceRelevance
" Thus, decarboxylase inhibition failed to alter the plasma half-life of levodopa."( Levodopa pharmacokinetics. Alterations after benserazide, a decarboxylase inhibitor.
Connor, JD; Doller, HJ; Dvorchik, BH; Lock, DR; Sloviter, RS; Vesell, ES,
)
0.39
" The present study, therefore, compared single dose kinetics and pharmacodynamic effects of three dosages of L-dopa/bensearazid-s."( [Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness].
Baas, H; Bergemann, N; Fischer, PA, 1994
)
0.29
" A moment analysis was also made to obtain pharmacokinetic parameters."( In vivo microdialysis to determine the relative pharmacokinetics of drugs.
Ichikawa, M; Matsuyama, K; Nakashima, M; Nakashima, MN; Sakurai, M; Sasaki, H; Zhao, MF, 1996
)
0.29
" Tolcapone had similar effects on plasma levodopa concentrations with the standard-release formulations: half-life and bioavailability increased approximately 2-fold compared with placebo, and maximum plasma concentration (Cmax) and time to Cmax (tmax) were unaffected, except for a slight increase in Cmax with the levodopa/benserazide 200/ 50 mg formulation."( The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
Aitken, J; Fotteler, B; Jorga, K; Nielsen, T; Schmitt, M; Zürcher, G, 1997
)
0.69
"A multiple-dose study was performed to assess the pharmacokinetic profile of a new levodopa/benserazide dual-release formulation (DRF) in comparison with a conventional slow-release formulation (SRF)."( Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects.
Crevoisier, C; Dingemanse, J; Gasser, UE; Lankhaar, G; Ouwerkerk, M, 1998
)
0.71
" Tolcapone increased the bioavailability (AUC 0-infinity) and apparent elimination half-life (t(1/2)) of levodopa by 80 and 40%, respectively, compared to placebo."( COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
Crevoisier, C; Gasser, UE; Hovens, SE; Jorga, K; van Giersbergen, PL, 1999
)
0.51
"The pharmacokinetic model which best described the data was a two-compartment open model with first-order absorption and possibly a lag-time."( Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.
Banken, L; Fotteler, B; Jorga, K; Snell, P; Steimer, JL, 2000
)
0.31
" The parameter estimates obtained agreed with those obtained from conventional pharmacokinetic studies and no subpopulation was shown to be at risk of either under- or over-exposure to tolcapone."( Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.
Banken, L; Fotteler, B; Jorga, K; Snell, P; Steimer, JL, 2000
)
0.31
" Plasma concentrations of levodopa and 3-O-methyldopa were measured by high-performance liquid chromatography for pharmacokinetic evaluation."( Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
Crevoisier, C; Metzger, B; Monreal, A; Nilsen, T, 2003
)
0.51
" Plasma concentrations of levodopa and 3-O-methyldopa were determined by high-performance liquid chromatography for pharmacokinetic evaluation."( Effects of food on the pharmacokinetics of levodopa in a dual-release formulation.
Calvi-Gries, F; Crevoisier, C; Nilsen, T; Zerr, P, 2003
)
0.32
" The main levodopa pharmacokinetic outcome variables were time to peak and peak plasma concentration, plasma elimination half-life, and the area under the plasma concentration-time curve."( Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
Albani, F; Baruzzi, A; Contin, M; Martinelli, P; Mochi, M; Riva, R, 2005
)
0.33
" Pharmacokinetic parameters were calculated for both treatments."( The effect of Madopar on the pharmacokinetics of ropinirole in healthy Chinese volunteers.
Bi, LL; Chen, XY; Jia, YY; Luo, XX; Wen, AD; Zhong, DF, 2007
)
0.34
" Pharmacokinetic parameters C(max), t(max), t(1/2z), mean residence time (MRT), AUC(0-tau), AUC(0-infinity), CL(z)/F and V(z)/F were determined under the non-compartmental model."( Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa).
Hang, TJ; Jia, L; Song, M; Wen, AD; Xu, XF; Yang, L; Zhang, TT, 2009
)
0.35
" For talipexole hydrochloride, there were no significant differences in the pharmacokinetic values between the two administrations."( Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa).
Hang, TJ; Jia, L; Song, M; Wen, AD; Xu, XF; Yang, L; Zhang, TT, 2009
)
0.35
" There was no significant difference in pharmacokinetic parameters, including t(1/2alpha), t(1/2beta), AUC(0-infinity), CL/F, C(max), t(max) and V/F."( Genetic polymorphism of catechol O-methyltransferase and pharmacokinetics of levodopa in healthy Chinese subjects.
Huang, PF; Ke, M; Lin, CH; Liu, YW; Wang, CL; Xu, Y; Yu, CX,
)
0.13
"0] kg/m2) completed the 4 treatment periods and had data available for pharmacokinetic and pharmacodynamic analyses."( Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Almeida, L; Costa, R; Falcão, A; Fernandes-Lopes, C; Loureiro, AI; Machado, R; Nunes, T; Rocha, JF; Soares-da-Silva, P; Torrão, L; Vaz-da-Silva, M; Wright, L, 2009
)
0.57
"The aims of the present study were to investigate the pharmacokinetic and pharmacodynamic (pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluate the effect of tolcapone on the pk/pd analysis of l-dopa in 1 patient with severe dyskinesias and fluctuations."( Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E, 2010
)
0.36
" The validated method was applied in a pharmacokinetic study with a levodopa/benserazide tablet formulation in healthy volunteers."( Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation.
Bonfim, RR; Byrro, RM; Cardoso, FF; César, Ida C; da Silva, EP; Gomes, SA; Mundim, IM; Pianetti, GA; Teixeira, Lde S, 2011
)
0.8
" The dispersible levodopa/benserazide formulation showed earlier time to Cmax and significantly higher Cmax for levodopa in plasma compared to the microtablets."( Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers.
Aquilonius, SM; Bäckström, T; Ehrnebo, M; Gomes-Trolin, C; Lewander, T; Nyholm, D; Nyström, C; Panagiotidis, G,
)
0.67
"The new levodopa/carbidopa microtablets had a pharmacokinetic profile that would allow for a convenient switch of therapy from standard tablets."( Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers.
Aquilonius, SM; Bäckström, T; Ehrnebo, M; Gomes-Trolin, C; Lewander, T; Nyholm, D; Nyström, C; Panagiotidis, G,
)
0.37
" Half-life was 58."( L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB, 2012
)
0.38
" L-DOPA t(max) and half-life are also similar to those reported in human."( L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB, 2012
)
0.38
" Changes of small magnitude but with possible clinical impact were found according to tmax and Cmax that tended to be lower in HP- patients and AUC0-t that was larger in the HP+ group."( Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection.
Adamiak-Giera, U; Białecka, M; Gawrońska-Szklarz, B; Madaliński, MH; Narożańska, E; Robowski, P; Schinwelski, M; Sołtan, W; Sławek, J,
)
0.13
" The main levodopa pharmacodynamic variables were the maximum percentage increase in tapping frequency over baseline values (ΔTapmax %) and the area under the tapping effect-time curve (AUCTap)."( Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson's disease.
Calandra-Buonaura, G; Capellari, S; Contin, M; Cortelli, P; Doria, A; Guaraldi, P; Lopane, G; Martinelli, P, 2016
)
0.43
"To compare the levodopa/carbidopa (LC) and levodopa/benserazide (LB) pharmacokinetic profiles following repeated doses of opicapone (OPC) administered apart from levodopa."( Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.
Almeida, L; Bonifácio, MJ; Falcão, A; Fauchoux, N; Loureiro, AI; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Sicard, É; Soares-da-Silva, P, 2017
)
0.71
"While several generic preparations of levodopa/carbidopa and levodopa/benserazide (LBD) are currently available, pharmacokinetic (PK) equivalence and therapeutic equivalence studies with levodopa generics are not available in Italy."( Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar).
Alessandroni, J; Bonassi, S; Bravi, D; Casali, M; Fossati, C; Grassini, P; Ialongo, C; Onofrj, M; Radicati, FG; Stocchi, F; Torti, M; Vacca, L, 2019
)
0.98

Compound-Compound Interactions

Resagiline combined with levodopa and benserazide hydrochloride can significantly lower the body's serum Hcy level, significantly raise IGF-1 levels, and significantly improve motor function in Parkinson's disease.

ExcerptReferenceRelevance
" Levodopa treatment, alone or in combination with two different dopa-decarboxylase inhibitors, benserazide and carbidopa, does not modify the renin response to posture or to frusemide."( Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease.
Dessi'-Fulgheri, P; Glorioso, N; Monaco, F; Rappelli, A; Tedde, R, 1978
)
0.48
"Since L-dopa in combination with a decarboxylase inhibitor is currently the most effective therapy available for treatment of Parkinson's disease, the authors compare the actual causes of death in a large series of treated Parkinson patients with a normal population and with previous studies."( Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor.
Siegfried, J; Zumstein, H, 1976
)
0.26
"Eighty-one Parkinsonic patients were treated with L-dopa alone and/or combined with Ro4-4602, during 27 to 60 months."( [5 years of experience in the treatment of parkinsonism with L-dopa and its combination with Ro4-4602].
Chouza, C; Gomensoro, JB; Romero, S, 1976
)
0.26
" In view of the observations made it is doubtful whether the therapeutic effect of 5-HTP combined with a peripheral decarboxylase inhibitor in depressions and myoclonus can in fact be atributed to activation of central serotonergic systems."( An unexpected effect of L-5 hydroxytryptophan-ethyl-ester combined with a peripheral decarboxylase inhibitor on human serum prolactin.
Korf, J; Lequin, RM; van Praag, HM, 1976
)
0.26
"5 g of levodopa daily for up to six months and in 30 patients receiving levodopa (800-1,000 mg) combined with a dopa decarboxylase inhibitor, benserazide (200-250 mg)."( Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations.
Rinne, UK; Siirtola, T; Sonninen, V, 1975
)
0.46
"In an open study 25 depressed patients were treated with L-5-hydroxytryptophan (L-5-HTP) either alone or in combination with a peripheral decarboxylase inhibitor."( L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression.
Battegay, R; Gastpar, M; Zmilacher, K, 1988
)
0.27
"To compare effectiveness of levodopa and levodopa combined with selegiline in treating early, mild Parkinson's disease."( Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Lees, AJ, 1995
)
0.29
"Treatment with levodopa and dopa decarboxylase inhibitor (arm 1) or levodopa and decarboxylase inhibitor in combination with selegiline (arm 2)."( Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Lees, AJ, 1995
)
0.29
"Levodopa in combination with selegiline seemed to confer no clinical benefit over levodopa alone in treating early, mild Parkinson's disease."( Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Lees, AJ, 1995
)
0.29
"Fifty cases in a treatment group were treated by acupuncture combined with madopar, and 30 cases in a control group treated by madopar only."( Fifty cases of Parkinson's disease treated by acupuncture combined with madopar.
Ren, XM, 2008
)
0.35
"To evaluate the effectiveness and safety of acupuncture combined with Madopar for the treatment of Parkinson's disease (PD), compared to the use of Madopar alone."( Effectiveness and safety of acupuncture combined with Madopar for Parkinson's disease: a systematic review with meta-analysis.
Chen, L; Chen, W; Dong, H; Geng, G; Li, T; Liu, H; Zhan, S; Zhang, Z, 2017
)
0.46
" Meta-analyses showed that acupuncture combined with Madopar for the treatment of PD can significantly improve the clinical effectiveness compared with Madopar alone (RR=1."( Effectiveness and safety of acupuncture combined with Madopar for Parkinson's disease: a systematic review with meta-analysis.
Chen, L; Chen, W; Dong, H; Geng, G; Li, T; Liu, H; Zhan, S; Zhang, Z, 2017
)
0.46
"Acupuncture combined with Madopar appears, to some extent, to improve clinical effectiveness and safety in the treatment of PD, compared with Madopar alone."( Effectiveness and safety of acupuncture combined with Madopar for Parkinson's disease: a systematic review with meta-analysis.
Chen, L; Chen, W; Dong, H; Geng, G; Li, T; Liu, H; Zhan, S; Zhang, Z, 2017
)
0.46
" The subjects in the control group received only levodopa and benserazide hydrochloride treatment, while the observation group was treated with Resagiline in combination with the clinical control group."( Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson's disease.
Gao, F; Gao, L; Miao, J; Yang, Y, 2023
)
1.41
"In patients with Parkinson's disease who are in the middle and late stages of the disease, the administration of Resagiline combined with levodopa and benserazide hydrochloride can significantly lower the body's serum Hcy level, significantly raise IGF-1 levels, and significantly improve motor function in patients with Parkinson's disease."( Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson's disease.
Gao, F; Gao, L; Miao, J; Yang, Y, 2023
)
1.36

Bioavailability

Tolcapone had similar effects on plasma levodopa concentrations with the standard-release formulations. Half-life and bioavailability increased approximately 2-fold compared with placebo. In conclusion, the novel COMT inhibitor BIA 3-202 was well tolerated.

ExcerptReferenceRelevance
" enhanced bioavailability and prolonged plasma half-life of L-DOPA, pronounced DOPA sparing effect and blockade of 3-OMD formation."( Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues.
Colzi, A; Da Prada, M; Zürcher, G, 1990
)
0.28
" The negative aspects of Madopar HBS are a lower bioavailability that means a dosage increase and a longer latency for the therapeutic response in the morning."( Long-term treatment with Madopar HBS in parkinsonians with fluctuations.
Aljanati, R; Buzó, R; Caamaño, JL; Chouza, C; De Medina, O; Fernandez, A; Plachín, V; Romero, S; Scaramelli, A, 1990
)
0.28
"The bioavailability of levodopa-benserazide in a standard capsule and a new dispersible tablet was compared in Parkinsonian patients, with (n = 8) and without (n = 8) swallowing difficulties."( Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia.
Bayer, AJ; Day, JJ; Finucane, P; Pathy, MS, 1988
)
0.79
" The clinical response to Madopar HBS was delayed and brief; the relative bioavailability was only 50%."( Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Jenner, P; Malcolm, SL; Marion, MH; Marsden, CD; Quinn, NP; Stocchi, F, 1987
)
0.51
" In comparison with standard Madopar the rate of absorption is reduced, providing lower peak concentrations of L-dopa."( Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers.
Allen, JG; Bird, H; Malcolm, SL; Marion, MH; Marsden, CD; O'Leary, CG; Quinn, NP, 1987
)
0.27
" The mean relative bioavailability (versus standard Madopar) was 58 and 67% (value normalized to dose) for one and two HBS capsules, respectively."( Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers.
Crevoisier, C; Da Prada, M; Hoevels, B; Zürcher, G, 1987
)
0.27
" In nine subjects who completed the trial, the clinical response, occurrence of dyskinesias and of nausea and vomiting, were similar with both treatments, although peak plasma levodopa concentration and levodopa bioavailability were greater on levodopa-domperidone than on levodopa-carbidopa."( Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease.
Langdon, N; Malcolm, PN; Parkes, JD, 1986
)
0.27
" There were no statistically significant differences in the cumulative amount absorbed of drug and the absorption rate in the presence or absence of Madopar."( Lack of an effect of Madopar on the disposition of tolcapone and its 3-O-methylated metabolite in rats.
Fukazawa, H; Funaki, T; Kuruma, I; Onodera, H; Tagami, C; Tsukamoto, Y; Ushiyama, N, 1995
)
0.29
" These findings support the notion that tolcapone has the ability to enhance striatal dopamine neurotransmission by increasing L-dopa bioavailability through peripheral and central inhibition of L-dopa O-methylation, as well as by blocking the central conversion of dopamine into 3-methoxytyramine."( Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
Da Prada, M; Napolitano, A; Zürcher, G, 1995
)
0.29
" Due to a lower bioavailability of the slow release formulation--the latter is based on the "hydrodynamically balanced system" (HBS)--, the patients remained initially on their time schedule of drug intake but received a higher dose of L-DOPA slow release compared to the preceding L-DOPA standard therapy."( [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
Eichhorn, TE; Kohnen, R; Oertel, WH; Poewe, W; Schrag, A; Selzer, R; Trenkwalder, C, 1995
)
0.56
" Tolcapone had similar effects on plasma levodopa concentrations with the standard-release formulations: half-life and bioavailability increased approximately 2-fold compared with placebo, and maximum plasma concentration (Cmax) and time to Cmax (tmax) were unaffected, except for a slight increase in Cmax with the levodopa/benserazide 200/ 50 mg formulation."( The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
Aitken, J; Fotteler, B; Jorga, K; Nielsen, T; Schmitt, M; Zürcher, G, 1997
)
0.69
" Inhibition of catechol-O-methyltransferase by tolcapone has been shown to increase levodopa bioavailability and plasma elimination half life, thereby prolonging the efficacy of levodopa."( Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Baas, H; Beiske, AG; Ghika, J; Jackson, M; Oertel, WH; Poewe, W; Ransmayr, G, 1998
)
0.3
" The bioavailability was significantly increased by 40% (AUC0-infinity=6."( Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects.
Crevoisier, C; Dingemanse, J; Gasser, UE; Lankhaar, G; Ouwerkerk, M, 1998
)
0.49
" Tolcapone increased the bioavailability (AUC 0-infinity) and apparent elimination half-life (t(1/2)) of levodopa by 80 and 40%, respectively, compared to placebo."( COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
Crevoisier, C; Gasser, UE; Hovens, SE; Jorga, K; van Giersbergen, PL, 1999
)
0.51
" The absorption of the drug was shown to be rapid and concomitant food intake had only a minor effect on the relative bioavailability (10-20% reduction compared with fasting)."( Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.
Banken, L; Fotteler, B; Jorga, K; Snell, P; Steimer, JL, 2000
)
0.31
" The relative bioavailability (Madopar DR vs."( Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
Crevoisier, C; Metzger, B; Monreal, A; Nilsen, T, 2003
)
0.51
" In conclusion, the novel COMT inhibitor BIA 3-202 was well tolerated and significantly increased the bioavailability of levodopa and reduced the formation of 3-OMD when administered with standard release levodopa/benserazide."( Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.
Almeida, L; Falcão, A; Loureiro, A; Machado, R; Maia, J; Silveira, P; Soares-da-Silva, P; Torrão, L; Vaz-da-Silva, M; Wright, L, 2003
)
0.72
" Long-term levodopa administration results in an increased levodopa plasma bioavailability in PD patients."( Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
Muhlack, S; Müller, T; Przuntek, H; Twiehaus, S; Welnic, J; Woitalla, D, 2004
)
0.32
" Catechol-O-methyltransferase (COMT) inhibitors increase the half-life and bioavailability of levodopa, providing more continuous dopamine receptor stimulation."( Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
Aguilar, E; Bonastre, M; Marin, C; Obeso, JA; Tolosa, E, 2005
)
0.33
"The aim of the study was to investigate the potential effect of short, moderate intensity (≤70% maximum heart rate) cyclette exercise on levodopa (LD)/dopa decarboxylase inhibitor bioavailability and motor response in a subgroup of Parkinson disease (PD) patients presenting a moderate-to-severe delay in fasting morning LD dose absorption and matched motor response."( The effect of a clinically practical exercise on levodopa bioavailability and motor response in patients with Parkinson disease.
Albani, F; Baruzzi, A; Contin, M; Lopane, G; Martinelli, P; Scaglione, C,
)
0.13
"The aim of this study was to evaluate the fasting bioavailability of a new generic formulation of levodopa 200 mg/benserazide 50 mg tablets (test) and compare this generic formulation with the branded formulation (reference) to meet regulatory criteria for marketing the test product in Argentina."( Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.
Assefi, AR; Bertuola, R; Czerniuk, P; Di Girolamo, G; Keller, GA; Spatz, JG, 2011
)
0.82
"To compare bioavailability and pharmacokinetics of single doses of 3 different levodopa formulations given orally in healthy volunteers."( Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers.
Aquilonius, SM; Bäckström, T; Ehrnebo, M; Gomes-Trolin, C; Lewander, T; Nyholm, D; Nyström, C; Panagiotidis, G,
)
0.37
" However, bioavailability of drugs varies between species and it is unknown how plasma L-DOPA levels providing therapeutic benefit in the non-human primate compare to those having similar actions in PD patients."( L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB, 2012
)
0.38
"Our results show an impaired LD bioavailability from Mucuna preparation, as expected by the lacking aromatic amino acid decarboxylase inhibitors coadministration, which might explain the suggested lower dyskinetic potential of Mucuna compared with standard LD formulations."( Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations.
Contin, M; Guarino, M; Iannello, C; Lopane, G; Passini, A; Poli, F,
)
0.13
"Opicapone, as once-daily oral evening regimen and/or 1 h apart from levodopa therapy, increases the bioavailability of levodopa associated with its pronounced, long-lasting and sustained catechol-O-methyltransferase inhibition."( Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.
Almeida, L; Bonifácio, MJ; Falcão, A; Fauchoux, N; Loureiro, AI; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Sicard, É; Soares-da-Silva, P, 2017
)
0.46
" The challenges are to increase the therapeutic efficiency, the bioavailability and decreasing the unfavourable side effects of Levodopa drug."( Nanocarrier for levodopa Parkinson therapeutic drug; comprehensive benserazide analysis.
Etminan, N; Rahmanifar, E; Yoosefian, M, 2018
)
0.72
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Two dosage strengths are available: 100 mg levodopa plus 25 mg benserazide and 50 mg levidopa plus 12. Studies were performed at 5-7 days post lesion (group 1 animals), at 21 days (group 2) and at the same time but following 7 days dosing with LDME plus benserazide (group 3)

ExcerptRelevanceReference
" Mean daily maintenance dosage was 612."( Levodopa/benserazide ('Madopar') combination therapy in elderly patients with parkinsonism.
Carlyle, D; Williams, BO, 1979
)
0.68
" Reduction of levodopa dosage to one sixth with the aid of a peripheral decarboxylase inhibitor (benserazide) largely eliminated autoimmune haemolysis while maintaining adequate control of neurologic symptoms."( Dose-related levodopa-induced haemolytic anaemia.
Enström, MS; Liedén, G; Linström, FD, 1977
)
0.47
" With both drugs, Madopar or Sinemet, an optimum therapeutic result was obtained with relatively small doses of L-dopa (the reduction in L-dopa dosage amounting to about 80%)."( [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
Birkmayer, W; Mentasti, M; Podiwinsky, F; Riederer, P, 1979
)
0.48
" The treatment periods were 12 weeks; similar dosage schedules were used, with doses that induced equal levels of plasma levodopa in both combinations."( Levodopa with benserazide or carbidopa in Parkinson disease.
Mölsä, P; Rinne, UK, 1979
)
0.62
" After pretreatment with a peripheral DOPA-decarboxylase inhibitor or high dosage of cold DOPA, the distribution pattern was not modified but the levels of radioactivity were greatly enhanced."( Autoradiographic distribution study of 14C-DOPA in cat brain.
Cassano, GB; Fornaro, P; Papeschi, R; Placidi, GF, 1976
)
0.26
" A reduced mean L-Dopa dosage was ruled out as the cause of this deterioration."( Study of deterioration in long-term treatment of parkinsonism with L-dopa plus decarboxylase inhibitor.
Bass-Verrey, F; Ludin, HP, 1976
)
0.26
" The excitability of the superior cervical ganglion of the rat was not diminished after a three-day treatment with L-Dopa, Benseraside (Ro 4-4602/1) and Iproniazid, at a dosage below the toxic level (table I)."( [Endogenous catecholamines and excitability of the superior cervical ganglion of the rat (author's transl)].
Burlet, DB, 1976
)
0.26
" Observations were repeated with varying dosage patterns, showing variations but no substantial changes or disappearance of the symptoms described."( [Long-term syndrome in the treatment of parkinsonism with L-dopa].
Chouza, C; Gomensoro, JB; Romero, S, 1975
)
0.25
" Patients were allocated at random to treatment with either levodopa + benserazide ratio 4:1 (Madopar) or levodopa + carbidopa ratio 10:1 (Sinemet) using dosage schedules recommended by the manufacturers which they had to adhere to for 6 months."( Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.
Birket-Smith, E; Dupont, E; Hansen, E; Mikkelsen, B; Pakkenberg, H; Presthus, J; Rautakorpi, I; Riman, E; Rinne, UK, 1976
)
0.49
" The results of the substitution phase show that combined treatment permitted a mean reduction of the levodopa dosage by 40%, without deterioration of therapeutic response."( Primary combination therapy of early Parkinson's disease. A long-term comparison between the combined regimen bromocriptine/levodopa and levodopa monotherapy--first interim report.
Kraus, PH; Letzel, H; Przuntek, H; Schwarzmann, D; Welzel, D, 1992
)
0.28
" It is suggested that chlormethiazole is safe to use as a hypnotic at this dosage in this group of patients with Parkinson's disease, while temazepam did not appear to be effective as a hypnotic at this dosage."( A single-dose study of the pharmacodynamic effects of chlormethiazole, temazepam and placebo in elderly parkinsonian patients.
Ashwood, TJ; Bateman, DN; Tulloch, JA; Woodhouse, KW, 1991
)
0.28
" When levodopa alone, or levodopa plus benserazide, was given as an acute challenge to animals receiving the same treatment chronically, it was found that levodopa alone still produced increases in striatal dopamine, DOPAC and HVA in those animals dosed chronically on levodopa, but it was less effective in this respect when given with benserazide to the animals dosed with levodopa plus benserazide."( The effect of benserazide on the peripheral and central distribution and metabolism of levodopa after acute and chronic administration in the rat.
Kent, AP; Stern, GM; Webster, RA, 1990
)
0.91
" The negative aspects of Madopar HBS are a lower bioavailability that means a dosage increase and a longer latency for the therapeutic response in the morning."( Long-term treatment with Madopar HBS in parkinsonians with fluctuations.
Aljanati, R; Buzó, R; Caamaño, JL; Chouza, C; De Medina, O; Fernandez, A; Plachín, V; Romero, S; Scaramelli, A, 1990
)
0.28
" The equivalent L-dopa dosage had to be increased by 56% (29-100%) with Madopar HBS while mean dopamine levels increased in four patients (by 47-257%) without the occurrence of peripheral side-effects."( Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
Ceballos-Baumann, AO; Eckert, W; von Kummer, R; Weicker, H, 1990
)
0.57
" In 13 patients a considerable diminution in nocturnal akinesia and in the frequency of waking up was reached with a mean dosage of 308 mg of Madopar HBS."( Madopar HBS in nocturnal symptoms of Parkinson's disease.
Jansen, EN; Meerwaldtt, JD, 1990
)
0.28
" The results suggest, the BH4 in the dosage used, is not effective in the treatment of Parkinson's disease."( Tetrahydrobiopterin and Parkinson's disease.
Dissing, IC; Gerdes, AM; Güttler, F; Lou, H; Lykkelund, C; Pakkenberg, H; Rasmussen, V, 1989
)
0.28
" Thereafter, selegiline was added in a progressively increasing dosage up to a maximum of 10 mg/day during 4 months, with the aim of a) further improving the long-term results and b) reducing the doses of the new formula of L-DOPA."( Combination of selegiline and controlled release levodopa in the treatment of fluctuations of clinical disability in parkinsonian patients.
Aljanati, R; Buzo, R; Caamaño, JL; Chouza, C; De Medina, O; Fernandez, A; Romero, S; Scaramelli, A, 1989
)
0.28
" The optimal therapeutic dosage of Sinemet CR was equal to that of Madopar HBS but 12% higher than that of standard Madopar."( Treatment of early Parkinson's disease with controlled-release levodopa preparations.
Rinne, JO; Rinne, UK, 1989
)
0.28
" The effects of L-Dopa dosage adjustments after hospitalization were particularly considered."( [The problems of L-dopa therapy in the course of Parkinson syndrome].
Emskötter, T; Heidenreich, C; Lachenmayer, L, 1989
)
0.28
" Only in 11% of cases, an augmentation of the dopa medication was found to be effective in improving the clinical syndrome, whereas in 43%, a substantial reduction of dosage was necessary and resulted in a marked improvement of the clinical syndrome."( [The problems of L-dopa therapy in the course of Parkinson syndrome].
Emskötter, T; Heidenreich, C; Lachenmayer, L, 1989
)
0.28
" Plasma ALAAD 2 hours after dosing was normal in Groups I and II."( Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
Boomsma, F; Hovestadt, A; Man in 't Veld, AJ; Meerwaldt, JD; Schalekamp, MA, 1989
)
0.28
" The model is then used to optimize the dosage regimen for each patient individually (according to the clinical particularities and needs of each patient) with respect to an objective function which includes the symptoms dynamically and the total amount of levodopa which is to be administered."( Optimization of symptomatic therapy in Parkinson's disease.
Albani, C; Hacisalihzade, SS; Mansour, M, 1989
)
0.28
" Even better results could be accomplished in an extended trial attempting to establish the best dosage ratio of the combination, possibly admitting increased dosage."( A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson's disease.
Aljanati, R; Caamaño, JL; Chouza, C; de Medina, O; Romero, S; Scaramelli, A, 1988
)
0.27
" Administration in daily dosage of 10 mgs produces an almost complete inhibition of the enzyme."( R-(-)-deprenyl and parkinsonism.
Yahr, MD, 1987
)
0.27
" During the first month the dosage titration was aimed at finding the optimal therapeutic effect."( Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy.
Aymard, N; Holzer, J; Rondot, P; Ziegler, M, 1987
)
0.27
"Madopar HBS (125 mg) is a controlled-release dosage form with 100 mg L-dopa and 25 mg benserazide."( The hydrodynamically balanced system: a novel principle of controlled drug release.
Erni, W; Held, K, 1987
)
0.5
" At the beginning the patients were switched from standard Madopar to Madopar HBS, initially keeping constant L-dopa dosage and the number of daily doses."( Open clinical study of Madopar HBS.
Ludin, HP, 1987
)
0.27
" However, with the new formulation the dosage had to be increased by 86% on average as compared with standard Madopar."( Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study.
D'Andrea, G; Durisotti, C; Ferro-Milone, F; Lion, P; Lorizio, A; Nordera, GP, 1987
)
0.27
" For the first few days (up to 1 week) dosage and number of daily intakes of HBS were the same as those of the standard formulation."( Preliminary experience with Madopar HBS: clinical observations and plasma levodopa concentrations.
Baas, H; Fischer, PA, 1987
)
0.27
" The overall increase in dosage of levodopa with Madopar HBS was 54% in comparison with the initial standard Madopar dosage."( Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
Heersema, T; Jansen, EN; Meerwaldt, JD; Speelman, JD; van Manen, J, 1987
)
0.27
" The frequency of drug intake was unaltered but daily dosage could be increased by 30% without increasing severity of abnormal movements to a similar degree."( [Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
Aymard, N; Holzer, J; Rondot, P; Ziegler, M, 1987
)
0.56
" In 13 patients a considerable diminution in nocturnal akinesia and in the frequency of waking up was reached with a mean dosage of 308 mg of Madopar HBS."( Madopar HBS in Parkinson patients with nocturnal akinesia.
Jansen, EN; Meerwaldt, JD, 1988
)
0.27
" Although the bioavailability after oral dosing is reduced as compared with standard Madopar (60-70%), this difference seems to be due to incomplete absorption rather than altered disposition of the drug."( Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers.
Allen, JG; Bird, H; Malcolm, SL; Marion, MH; Marsden, CD; O'Leary, CG; Quinn, NP, 1987
)
0.27
" At the end of the dosage adaptation phase (9 weeks) most patients improved; in patients with 'on-off' phenomenon, parkinsonism became less severe, on periods were longer, and fluctuations decrease; end-of-dose impairment resolved in 4 patients."( Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
Aljanati, R; Caamano, JL; Chouza, C; de Medina, O; Gonzales Panizza, V; Romero, S; Scarmelli, A, 1987
)
0.27
" The dosage was adjusted until optimal response was obtained."( Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
Dupont, E; Hansen, E; Jensen, NO; Mikkelsen, B; Mikkelsen, BO, 1987
)
0.54
" In all patients of the first group, after 3 months on stable 'optimal' dosage schedule, the previous L-dopa treatment was abruptly replaced, dose for dose, from one day to another by Madopar HBS, a new controlled-release form of Madopar."( Therapeutic value of Madopar HBS: judgment after 2 years experience.
Siegfried, J, 1987
)
0.27
" The dosage of drug was titrated at each visit to give minimum risk with acceptable benefit."( Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
Admani, AK; Cordingley, GJ; Harris, RI; Verma, S, 1985
)
0.27
" Pressor dose-response relationships for noradrenaline were the same before and after L-DOPA, as well as in cats pretreated with L-DOPA for 4 days."( On the mechanism of L-dopa-induced postural hypotension in the cat.
Dhasmana, KM; Spilker, BA, 1973
)
0.25
" In both men and women there tended to be a significant correlation between the initial log plasma PRL level while on neuroleptic maintenance treatment and the dosage received converted to chlorpromazine equivalents."( Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system.
Annable, L; Chouinard, G; Collu, R; Jones, BD, 1981
)
0.26
" Subsequently they were treated with either a mean dosage of 444 mg levodopa and benserazide (47 patients) or a combination of a mean of 298 mg levodopa and benserazide plus 17 mg bromocriptine (32 patients)."( [Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study].
Fischer, PA; Majer, M; Przuntek, H; Welzel, D, 1984
)
0.49
" Following effective stereotaxic surgery, drug therapy should be continued with reduced dosage of the drugs."( [Combined (surgical and drug) therapy of parkinsonism].
Iadgarov, IS; Kandel', EI, 1984
)
0.27
"L-Tryptophan at moderately low dosage (20 mg/kg) reduced the activity of rats taken during a dark period (red light) and put into an open field illuminated by bright white light."( The effect of L-tryptophan on motor activity and its prevention by an extracerebral decarboxylase inhibitor and by 5-HT receptor blockers.
Curzon, G; Drewitt, PN; Tricklebank, MD, 1980
)
0.26
" PRL increase after benserazide was compared with PRL response after carbidopa at the same dosage in untreated parkinsonian patients."( Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
Agnoli, A; Baldassarre, M; D'Urso, R; De Giorgio, G; Falaschi, P; Rocco, A; Ruggieri, S, 1982
)
0.59
" Two dosage strengths are available: 100 mg levodopa plus 25 mg benserazide and 50 mg levodopa plus 12."( [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
Dessibourg, CA; Gachoud, JP, 1995
)
0.79
" A three times greater dosage of L-dopa-s."( [Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness].
Baas, H; Bergemann, N; Fischer, PA, 1994
)
0.29
" No addiction to the drugs, and in particular no need of a dosage increase was observed during the whole period of 18 months."( [Restless legs syndrome. Report of experience].
Grandjean, P, 1993
)
0.29
" The drugs were dosed according to the individual need of the patients."( Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients.
Andersen, A; Boas, J; Boisen, E; Borgmann, R; Buch, D; Dupont, E; Helgetveit, AC; Kjaer, MO; Kristensen, TN; Mikkelsen, B; Pakkenberg, H; Presthus, J; Stien, R; Worm-Petersen, J, 1996
)
0.29
" Studies were performed at 5-7 days post lesion (group 1 animals), at 21 days (group 2) when denervation supersensitivity was evident by contralateral turning to apomorphine and at the same time but following 7 days dosing with LDME plus benserazide (group 3)."( Effect of L-dopa alone and with benserazide on the spontaneous activity of striatal neurones in normal and 6-hydroxydopamine-lesioned rats.
Chang, WY; Webster, RA, 1997
)
0.76
" Plasma levels of levodopa, 3-O-methyldopa (3-OMD) and 3,4-dihydroxyphenylacetic acid (DOPAC) were determined before benserazide treatment and during all benserazide dosing regimens, as existing endogenously and after administration of 250 mg levodopa."( Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics.
Crevoisier, C; Dingemanse, J; Kleinbloesem, CH; Wood, ND; Zürcher, G, 1997
)
0.83
"Two patients with Parkinson's disease repeatedly increased their levodopa dosage on their own to 1500-2000 mg/day to reach and sustain a state of euphoria, regardless of the fact that dosages of 400-800 mg/day were sufficient to suppress their parkinsonian symptoms."( Levodopa dependence and abuse in Parkinson's disease.
Spigset, O; von Schéele, C,
)
0.13
" As a consequence, levodopa dosage might be increased and the interdose interval progressively shortened."( Clinical implications of sustained dopaminergic stimulation.
Barbato, L; Berardelli, A; Bonamartini, A; Manfredi, M; Patsalos, PN; Ruggieri, S; Stocchi, F, 1994
)
0.29
" Daily levodopa dosage requirements decreased significantly."( Highlights of the North American and European experiences.
Goetz, CG, 1998
)
0.3
" L-DOPA was used in the form of the drug madopar in dosage of 25,5 mg/kg of body mass daily."( [Influence of L-DOPA on rat brain depending on individual behavioral features].
Gershteĭn, LM; Sergutina, AV, 2004
)
0.32
" Finally, after determination of basal levels of 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 5-hydroxyindole-3-acetic acid (5-HIAA) in the rats, the rats were dosed with benserazide followed by l-3,4-dihydroxyphenylalanine (l-DOPA)."( Evaluation of an osmotic pump for microdialysis sampling in an awake and untethered rat.
Cooper, JD; Davies, MI; Heppert, KE; Lunte, SM, 2007
)
0.53
" Oral levodopa dosing was increased in 28% of patients; the primary outcome remained significant when these patients were excluded."( Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Amar, K; Eggert, K; Kuoppamäki, M; Leinonen, M; Luotonen, L; Nissinen, H; Oertel, W; Skogar, O, 2010
)
0.65
" We now report on the choice of dopa decarboxylase inhibitors, dose and the time of dosing relationships of carbidopa, benserazide and L-alpha-methyl dopa (L-AMD) in potentiating the effects of L-DOPA in the 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP)-treated common marmoset."( The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
Fisher, R; Jackson, MJ; Jenner, P; Rose, S; Tayarani-Binazir, KA; Zoubiane, G, 2010
)
0.57
" The microtablets are intended for individualized dosing of levodopa/carbidopa in Parkinson disease by means of an electronic dose dispenser with a built-in diary for symptom registration."( Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers.
Aquilonius, SM; Bäckström, T; Ehrnebo, M; Gomes-Trolin, C; Lewander, T; Nyholm, D; Nyström, C; Panagiotidis, G,
)
0.37
" The Unified Parkinson's Disease Rating Scale scores, TCM symptoms scores, quality of life, change of Madopar's dosage and the toxic and adverse effects of Madopar will be observed during a 3-month treatment period and through a further 6-month follow-up period."( Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: study protocol of a multicenter, open-label, randomized active-controlled trial.
Ma, YZ; Shen, XM; Zhang, J, 2013
)
0.39
" Rats were dosed orally with Tozadenant, a selective A2A receptor antagonist, and three different doses of Radiprodil, an NR2B-selective NMDA receptor antagonist."( Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs.
De Wolf, C; Downey, P; Michel, A; Scheller, D; Schwarting, R; Van Damme, X, 2015
)
0.42
"  Madopar dosage was maintained in both groups."( The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia.
Cao, LD; Guo, G; Wu, QY; Xu, S, 2016
)
0.74
"Despite extensive research in the field of gastroretentive dosage forms, this "holy grail" of oral drug delivery yet remained an unmet goal."( Influence of Postprandial Intragastric Pressures on Drug Release from Gastroretentive Dosage Forms.
Hoppe, M; Koziolek, M; Schneider, F; Weitschies, W, 2018
)
0.48
" As LD/BH sustained release suspension can synchronize sustained release of multiple active ingredients by oral administration, the suspension presents promising oral dosage forms for geriatric patients with PD."( Development, Optimization, and Evaluation In Vitro/In Vivo of Oral Liquid System for Synchronized Sustained Release of Levodopa/Benserazide.
Ding, YP; Lai, WL; Liu, HF; Qu, Y; Wang, L; Xin, YR; Xu, Y; Zhu, FQ; Zhu, Y, 2019
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitorAn EC 4.1.1.* (carboxy-lyase) inhibitor that interferes with the action of aromatic-L-amino-acid decarboxylase (EC 4.1.1.28).
antiparkinson drugA drug used in the treatment of Parkinson's disease.
dopaminergic agentA drug used for its effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
carbohydrazideA hydrazide consisting of hydrazine carrying one or more carboacyl groups.
catecholsAny compound containing an o-diphenol component.
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
primary alcoholA primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency3.66520.100020.879379.4328AID488773; AID588453; AID588456
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624146
regulator of G-protein signaling 4Homo sapiens (human)Potency9.46620.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency28.51720.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
arylsulfatase AHomo sapiens (human)Potency3.38081.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.41250.035520.977089.1251AID504332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency35.48130.006026.168889.1251AID488953
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency24.70120.00378.618923.2809AID2667; AID2668
M-phase phosphoprotein 8Homo sapiens (human)Potency29.93490.177824.735279.4328AID488949
D(1A) dopamine receptorSus scrofa (pig)Potency23.28090.00378.108123.2809AID2667
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.75690.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)116.60000.11007.190310.0000AID1449628
Genome polyproteinCoxsackievirus B3 (strain Nancy)IC50 (µMol)2.40000.63001.37672.4000AID1317663
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)0.14000.00022.45859.9600AID1640021
Hexokinase-2Homo sapiens (human)IC50 (µMol)5.52005.52005.52005.5200AID1525106
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Zinc finger protein mex-5Caenorhabditis elegansEC50 (µMol)1,350.00001.30702.73954.1720AID2739
POsterior SegregationCaenorhabditis elegansEC50 (µMol)1,350.00002.201047.1808186.6810AID2738
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (41)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
apoptotic mitochondrial changesHexokinase-2Homo sapiens (human)
response to hypoxiaHexokinase-2Homo sapiens (human)
response to ischemiaHexokinase-2Homo sapiens (human)
fructose 6-phosphate metabolic processHexokinase-2Homo sapiens (human)
glycolytic processHexokinase-2Homo sapiens (human)
lactationHexokinase-2Homo sapiens (human)
negative regulation of mitochondrial membrane permeabilityHexokinase-2Homo sapiens (human)
positive regulation of angiogenesisHexokinase-2Homo sapiens (human)
regulation of glucose importHexokinase-2Homo sapiens (human)
glucose 6-phosphate metabolic processHexokinase-2Homo sapiens (human)
canonical glycolysisHexokinase-2Homo sapiens (human)
establishment of protein localization to mitochondrionHexokinase-2Homo sapiens (human)
maintenance of protein location in mitochondrionHexokinase-2Homo sapiens (human)
positive regulation of autophagy of mitochondrion in response to mitochondrial depolarizationHexokinase-2Homo sapiens (human)
cellular response to leukemia inhibitory factorHexokinase-2Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processHexokinase-2Homo sapiens (human)
carbohydrate phosphorylationHexokinase-2Homo sapiens (human)
glucose metabolic processHexokinase-2Homo sapiens (human)
intracellular glucose homeostasisHexokinase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (22)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
glucokinase activityHexokinase-2Homo sapiens (human)
hexokinase activityHexokinase-2Homo sapiens (human)
protein bindingHexokinase-2Homo sapiens (human)
ATP bindingHexokinase-2Homo sapiens (human)
glucose bindingHexokinase-2Homo sapiens (human)
fructokinase activityHexokinase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mitochondrionHexokinase-2Homo sapiens (human)
mitochondrial outer membraneHexokinase-2Homo sapiens (human)
centrosomeHexokinase-2Homo sapiens (human)
cytosolHexokinase-2Homo sapiens (human)
membraneHexokinase-2Homo sapiens (human)
sarcoplasmic reticulumHexokinase-2Homo sapiens (human)
intracellular membrane-bounded organelleHexokinase-2Homo sapiens (human)
mitochondrionHexokinase-2Homo sapiens (human)
cytosolHexokinase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (70)

Assay IDTitleYearJournalArticle
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1881900Inhibition of PKM2 (unknown origin) Asp177, Asp178, Ser362, Thr328, Asn75, Ile51, Thr129 residues2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1525106Inhibition of HK2 (unknown origin) using glucose-6-phosphate dehydrogenase as substrate preincubated for 10 mins followed by substrate addition2019Journal of natural products, 05-24, Volume: 82, Issue:5
Strepantibins A-C: Hexokinase II Inhibitors from a Mud Dauber Wasp Associated Streptomyces sp.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID481440Dissociation constant, pKa of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1317663Inhibition of recombinant Coxsackievirus B3 3C protease expressed in Escherichia coli BL21 (DE3) preincubated for 5 mins followed by addition of NMA-EALFQGPPVK-DNP-rrr-NH2 as substrate measured every 10 mins for 2 hrs by FRET-based enzyme assay2016European journal of medicinal chemistry, Sep-14, Volume: 1202,3,4-Trihydroxybenzyl-hydrazide analogues as novel potent coxsackievirus B3 3C protease inhibitors.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID481444Octanol-water partition coefficient, log P of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID481446Effective permeability across human jejunum2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID481442Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID702756Antiparkinsonian activity in C57BL/6 mouse assessed as decrease in MPTP-induced vertical rearing behavior impairment at 12.5 mg/kg, ip administered 30 mins on day 7 post MPTP challenge2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID481441Aqueous diffusivity at 37C2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1345275Human L-Aromatic amino-acid decarboxylase (Catecholamine turnover)2012PloS one, , Volume: 7, Issue:2
Identification by virtual screening and in vitro testing of human DOPA decarboxylase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,044)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990562 (53.83)18.7374
1990's186 (17.82)18.2507
2000's116 (11.11)29.6817
2010's146 (13.98)24.3611
2020's34 (3.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 68.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index68.64 (24.57)
Research Supply Index7.15 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index121.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (68.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials162 (14.56%)5.53%
Reviews27 (2.43%)6.00%
Case Studies94 (8.45%)4.05%
Observational3 (0.27%)0.25%
Other827 (74.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (17)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1b Sequential Open Label Dose-Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia and Sickle Cell Disease [NCT04432623]Phase 1/Phase 236 participants (Anticipated)Interventional2020-10-05Recruiting
Fasting Comparative Bioavailability of Two Tablet Formulations of Levodopa /Benserazide in Healthy Volunteers: A Single- Dose Randomized- Sequence, Open -Label Crossover Study [NCT01327261]Phase 424 participants (Actual)Interventional2009-08-31Completed
Mucuna Pruriens Therapy in Parkinson's Disease: a Double-blind, Placebo-controlled, Randomized, Crossover Study. [NCT02680977]Phase 218 participants (Actual)Interventional2016-02-29Completed
L-Dopa Modulated Striatal Functional Connectivity in Schizotypal Adults: a Randomized Double-blind Placebo-controlled Study [NCT03333369]Early Phase 165 participants (Actual)Interventional2014-05-15Completed
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 3-202 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide (Madopar® HBS 125): a Double-blind, Randomised, Four-way Crossover, Placebo-controlled Stu [NCT02778594]Phase 117 participants (Actual)Interventional2005-09-30Completed
Effect of Fecal Microbiota Transfer on Progression of Parkinson Disease [NCT05204641]Phase 1/Phase 260 participants (Actual)Interventional2021-11-01Active, not recruiting
Effect of Dopaminergic Medication on Recovery of Aphasia [NCT00941265]12 participants (Actual)Interventional2007-02-28Completed
Molecular Basis of Loss Aversion [NCT06034158]60 participants (Anticipated)Interventional2023-09-18Recruiting
Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in Parkinson's Disease Patients With Delayed ON: a Multicenter Randomized Open-label Cross-over Trial [NCT02769793]Phase 440 participants (Actual)Interventional2015-06-30Completed
Clinical and Pharmacokinetics Study to Evaluate the Therapeutic Equivalence and Bioequivalence of Levodopa Benserazide Generic Formulation (Teva Italia) Versus the Originator (Madopar®) [NCT02741947]Phase 444 participants (Actual)Interventional2014-04-30Completed
Swiss Restless Legs Syndrome Trial (SRLS) A Double-blind, Randomised, Crossover Trial Investigating the Efficacy and Safety of the Dopamine Agonist Pramipexole (Sifrol®, 0.25-0.75 mg Per Day) Versus Levodopa / Benserazide (Madopar® DR, 125-375 mg Per Day) [NCT00144209]Phase 358 participants (Actual)Interventional2003-02-28Completed
"Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With Wearing-off Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo- and Active-controlled, Parallel-group, Multice [NCT01568073]Phase 3600 participants (Actual)Interventional2011-03-31Completed
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects [NCT01533116]Phase 152 participants (Actual)Interventional2009-03-31Completed
"Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With Wearing-off Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinica [NCT01227655]Phase 3427 participants (Actual)Interventional2011-03-31Completed
Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics of a Single-dose of Immediate Release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects [NCT02169414]Phase 174 participants (Actual)Interventional2010-02-28Completed
A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study in Healthy Volunteers to Investigate the Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benser [NCT03097211]Phase 138 participants (Actual)Interventional2006-07-17Completed
"A Multicentre, Double-blind, Randomised, Active- and Placebo-controlled Trial to Investigate the Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With Wearingoff Phenomenon Treated With Levodopa/Carbidopa or Levodopa/Benserazide" [NCT03103399]Phase 2254 participants (Actual)Interventional2006-09-26Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01227655 (4) [back to overview]Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) Compared With Placebo, When Administered With the Existing Treatment of L-DOPA Plus a DDCI (DOPA Decarboxylase Inhibitor)
NCT01227655 (4) [back to overview]Non-motor Symptoms Scale (NMSS)
NCT01227655 (4) [back to overview]Parkinson's Disease Sleep Scale (PDSS)
NCT01227655 (4) [back to overview]UPDRS (Unified Parkinson's Disease Rating Scale) Sections I (ON), II (ON and OFF), and III (ON)
NCT01533116 (5) [back to overview]AUEC0-24 - Area Under the Effect-time Curve (AUEC) to 24 h Post-dose
NCT01533116 (5) [back to overview]tEmax - Time of Occurrence of Maximum Observed Effect on S-COMT Activity
NCT01533116 (5) [back to overview]AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point
NCT01533116 (5) [back to overview]Cmax - Maximum Plasma Concentration
NCT01533116 (5) [back to overview]Tmax - Time to Maximum Plasma Concentration
NCT01568073 (4) [back to overview]Efficacy of 3 BIA 9-1067 (5 mg, 25 mg, and 50 mg) Compared With 200 mg of Entacapone or Placebo,
NCT01568073 (4) [back to overview]Non-motor Symptoms Scale (NMSS)
NCT01568073 (4) [back to overview]Parkinson's Disease Sleep Scale (PDSS)
NCT01568073 (4) [back to overview]Total UPDRS SCORE (I, II (ON), and III)
NCT02169414 (8) [back to overview]AUC0-∞ - Area Under the Plasma Concentration-time Curve (AUC) of Levodopa From Time Zero to Infinity (Levodopa/Benserazide)
NCT02169414 (8) [back to overview]AUC0-∞ - Area Under the Plasma Concentration-time Curve (AUC) of Levodopa From Time Zero to Infinity (Levodopa/Carbidopa)
NCT02169414 (8) [back to overview]AUC0-t - Area Under the Plasma Concentration-time Curve (AUC) of Levodopa From Time Zero to the Last Sampling Time at Which the Drug Concentration Was at or Above the Lower Limit of Quantification. (Levodopa/Benserazide)
NCT02169414 (8) [back to overview]AUC0-t - Area Under the Plasma Concentration-time Curve (AUC) of Levodopa From Time Zero to the Last Sampling Time at Which the Drug Concentration Was at or Above the Lower Limit of Quantification. (Levodopa/Carbidopa)
NCT02169414 (8) [back to overview]Cmax - Maximum Plasma Concentration of Levodopa (Levodopa/Benserazide )
NCT02169414 (8) [back to overview]Cmax - Maximum Plasma Concentration of Levodopa (Levodopa/Carbidopa)
NCT02169414 (8) [back to overview]Tmax - Time to Reach Maximum Plasma Concentration of Levodopa (Levodopa/Benserazide)
NCT02169414 (8) [back to overview]Tmax - Time to Reach Maximum Plasma Concentration of Levodopa (Levodopa/Carbidopa)

Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) Compared With Placebo, When Administered With the Existing Treatment of L-DOPA Plus a DDCI (DOPA Decarboxylase Inhibitor)

Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) compared with placebo, when administered with the existing treatment of L-DOPA plus a DDCI (DOPA decarboxylase inhibitor), in patients with PD and end-of-dose motor fluctuations. The primary efficacy variable will be the change from baseline in absolute OFF-time at the end of the DB period. (NCT01227655)
Timeframe: 14-15 weeks

Interventionminutes (Mean)
BIA 9-1067 25 mg-102.8
BIA 9-1067 50 mg-124.0
Placebo-64.5

[back to top]

Non-motor Symptoms Scale (NMSS)

"The Non-motor Symptoms Scale (NMSS) consists of 30 questions, covering 9 dimensions, whereby each item is scored for severity and frequency: Severity None 0 Mild (symptoms present but causes little distress) 1 Moderate (some distress or disturbance to subject) 2 Severe (major source of distress or disturbance to subject) 3~Frequency Rarely (<1/wk) 1 Often (1/wk) 2 Frequent (several times per week) 3 Very Frequent (daily or all the time) 4~The product of frequency and severity is calculated for each item and each dimension score is defined as the sum of the frequency*severity of the respective items. If frequency or severity of a single item is missing, the domain score will not be calculated. The NMSS total score is defined as the sum of all domain scores.~The NMSS total score is calculated by adding all domain scores (0-360), and lower scores mean less disability." (NCT01227655)
Timeframe: 14-15 weeks

,,
Interventionunits on a scale (Mean)
BaselineVisit 5Visit 7
BIA 9-1067 25 mg38.233.735.0
BIA 9-1067 50 mg36.733.231.5
Placebo38.233.531.6

[back to top]

Parkinson's Disease Sleep Scale (PDSS)

"The Parkinson's disease Sleep Scale (PDSS) is a specific scale for the assessment of sleep disturbances in subjects with PD. The PDSS score is calculated as the sum of all single items. If one or two items are missing, they will be imputed with the mean of the non-missing items. If three or more items are missing, no imputation will be done and the score will be set to missing.~Subscale has 0-10 ratings, where 0 = severe and 10 = normal~The PDSS total score is a sum score of all 15 questions and ranges from 0 to 150, with lower scores meaning more disability." (NCT01227655)
Timeframe: 14-15 weeks

,,
Interventionunits on a scale (Mean)
BaselineVisit 5Visit 7
BIA 9-1067 25 mg95.7597.9998.79
BIA 9-1067 50 mg102.62103.05103.25
Placebo101.76107.11105.39

[back to top]

UPDRS (Unified Parkinson's Disease Rating Scale) Sections I (ON), II (ON and OFF), and III (ON)

"Total UPDRS SCORE (I, II (ON), and III) Change from Baseline to Endpoint~UPDRS I evaluation of mentation, behavior, and mood~UPDRS II self-evaluation of the activities of daily life (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, and cutting food~UPDRS III clinician-scored monitored motor evaluation The UPDRS I, II and III scores and subscores are calculated as the sum of all individual items. If one or two items in a scale are missing, they will be imputed with the mean of the non-missing items of that scale.~Subscale has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe~The final cumulative score will range from 0 (no disability) to 199 (total disability)." (NCT01227655)
Timeframe: 14-15 weeks

,,
Interventionunits on a scale (Mean)
BaselineEndpoint
BIA 9-1067 25 mg30.826.6
BIA 9-1067 50 mg31.728.7
Placebo31.528.1

[back to top]

AUEC0-24 - Area Under the Effect-time Curve (AUEC) to 24 h Post-dose

AUEC0-24 - Area under the effect-time curve (AUEC) to 24 h post-dose. (NCT01533116)
Timeframe: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h

Interventionpmol/mg Hb/h.h (Mean)
Placebo906
5 mg BIA 9-1067454
15 mg BIA 9-1067319
30 mg BIA 9-1067226

[back to top]

tEmax - Time of Occurrence of Maximum Observed Effect on S-COMT Activity

tEmax - time of occurrence of maximum observed effect on S-COMT activity COMT - Catechol-O-Methyltransferase (NCT01533116)
Timeframe: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h

Interventionhours (Mean)
Placebo8.12
5 mg BIA 9-10672.71
15 mg BIA 9-10674.67
30 mg BIA 9-10673.50

[back to top]

AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point

AUC0-t - area under the plasma concentration-time curve from time 0 to last observed concentration 3-OMD - 3-O-methyl-dopa - metabolite of L-DOPA (levodopa) AUC0-t (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® AUC0-t (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® AUC0-t (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® (NCT01533116)
Timeframe: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h

,,,
Interventionng.h/mL (Mean)
AUC0-t (Levodopa) Sinemet® 100/25AUC0-t (Levodopa) Prolopa® 100-25AUC0-t (3-OMD) Sinemet® 100/25AUC0-t (3-OMD) Prolopa® 100/25AUC0-t (BIA 9-1067) Sinemet® 100/25AUC0-t (BIA 9-1067) Prolopa® 100/25
15 mg BIA 9-10672952344228363473872836
30 mg BIA 9-1067275340561751262311011185
5 mg BIA 9-10673386411551476205223232
Placebo18372438763111371NANA

[back to top]

Cmax - Maximum Plasma Concentration

Cmax - maximum plasma concentration Cmax (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Cmax (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Cmax (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® (NCT01533116)
Timeframe: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h

,,,
Interventionng/mL (Mean)
Cmax (Levodopa) Sinemet® 100/25Cmax (Levodopa) Prolopa® 100-25Cmax (3-OMD) Sinemet® 100/25Cmax (3-OMD) Prolopa® 100/25Cmax (BIA 9-1067) Sinemet® 100/25Cmax (BIA 9-1067) Prolopa® 100/25
15 mg BIA 9-106712001727167206263281
30 mg BIA 9-10679441795115160310370
5 mg BIA 9-10671245210030736075.095.5
Placebo9851704456688NANA

[back to top]

Tmax - Time to Maximum Plasma Concentration

Tmax - time to maximum plasma concentration Tmax (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Tmax (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Tmax (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® (NCT01533116)
Timeframe: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h

,,,
Interventionhours (Median)
Tmax (Levodopa) Sinemet® 100/25Tmax (Levodopa) Prolopa® 100-25Tmax (3-OMD) Sinemet® 100/25Tmax (3-OMD) Prolopa® 100/25Tmax (BIA 9-1067) Sinemet® 100/25Tmax (BIA 9-1067) Prolopa® 100/25
15 mg BIA 9-10670.51.06.06.03.02.5
30 mg BIA 9-10671.01.08.04.04.03.0
5 mg BIA 9-10670.751.08.08.01.53.0
Placebo0.51.04.04.0NANA

[back to top]

Efficacy of 3 BIA 9-1067 (5 mg, 25 mg, and 50 mg) Compared With 200 mg of Entacapone or Placebo,

The primary efficacy variable will be the change from baseline in absolute OFF-time at the end of the DB period, This results refers when administered with the existing treatment of L-DOPA plus a DDCI, in patients with PD and end-of-dose motor fluctuations (NCT01568073)
Timeframe: 14 to 15 weeks

Interventionminutes (Mean)
Placebo-56.0
Entacapone-96.3
OPC 5mg-91.3
OPC 25mg-85.9
OPC 50mg-116.8

[back to top]

Non-motor Symptoms Scale (NMSS)

"The Non-motor Symptoms Scale (NMSS) consists of 30 questions, covering 9 dimensions, whereby each item is scored for severity and frequency: Severity None 0 Mild (symptoms present but causes little distress) 1 Moderate (some distress or disturbance to subject) 2 Severe (major source of distress or disturbance to subject) 3~Frequency Rarely (<1/wk) 1 Often (1/wk) 2 Frequent (several times per week) 3 Very Frequent (daily or all the time) 4~The product of frequency and severity is calculated for each item and each dimension score is defined as the sum of the frequency*severity of the respective items. If frequency or severity of a single item is missing, the domain score will not be calculated. The NMSS total score is defined as the sum of all domain scores.~The NMSS total score is calculated by adding all domain scores (0-360), and lower scores mean less disability." (NCT01568073)
Timeframe: 14 to 15 weeks

,,,,
Interventionunits on a scale (Mean)
BaselineVisit 5Visit 7Endpoint
Entacapone32.127.927.527.5
OPC 25mg39.834.034.634.4
OPC 50mg36.430.233.733.4
OPC 5mg36.130.229.529.5
Placebo38.833.432.332.0

[back to top]

Parkinson's Disease Sleep Scale (PDSS)

"The Parkinson's disease Sleep Scale (PDSS) is a specific scale for the assessment of sleep disturbances in subjects with PD. The PDSS score is calculated as the sum of all single items. If one or two items are missing, they will be imputed with the mean of the non-missing items. If three or more items are missing, no imputation will be done and the score will be set to missing.~Subscale has 0-10 ratings, where 0 = severe and 10 = normal~The PDSS total score is a sum score of all 15 questions and ranges from 0 to 150, with lower scores meaning more disability." (NCT01568073)
Timeframe: 14 to 15 weeks

,,,,
Interventionunits on a scale (Mean)
BaselineVisit 5Visit 7Endpoint (14 to 15 weeks)
Entacapone100.7102.5103.2102.8
OPC 25mg92.7101.7100.6100.4
OPC 50mg98.0100.2100.7100.9
OPC 5mg97.8103.8102.8102.9
Placebo97.597.697.798.5

[back to top]

Total UPDRS SCORE (I, II (ON), and III)

"Total UPDRS (Part I, II (ON) and III)~UPDRS I evaluation of mentation, behavior, and mood~UPDRS II self-evaluation of the activities of daily life (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, and cutting food~UPDRS III clinician-scored monitored motor evaluation The UPDRS I, II and III scores and subscores are calculated as the sum of all individual items. If one or two items in a scale are missing, they will be imputed with the mean of the non-missing items of that scale.~Subscale has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe~The final cumulative score will range from 0 (no disability) to 199 (total disability)." (NCT01568073)
Timeframe: 14 to 15 weeks

,,,,
Interventionunits on a scale (Mean)
Baseline (Day 0)Endpoint (14 to 15 weeks)Change from Baseline to Endpoint
Entacapone35.429.8-6.0
OPC 25mg40.132.0-7.6
OPC 50mg38.831.5-6.5
OPC 5mg38.231.0-7.6
Placebo37.632.1-5.6

[back to top]

AUC0-∞ - Area Under the Plasma Concentration-time Curve (AUC) of Levodopa From Time Zero to Infinity (Levodopa/Benserazide)

Levodopa pharmacokinetic parameters following a single oral administration of 100/25 mg levodopa/benserazide administered 12 h after BIA 9-1067 (5 mg, 15 mg and 50 mg) or placebo on Day 18 (NCT02169414)
Timeframe: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose.

Interventionng.h/mL (Mean)
Placebo2360.3
BIA 9-1067 5 mg2660.9
BIA 9-1067 15 mg3655.9
BIA 9-1067 50 mg3979.5

[back to top]

AUC0-∞ - Area Under the Plasma Concentration-time Curve (AUC) of Levodopa From Time Zero to Infinity (Levodopa/Carbidopa)

Levodopa pharmacokinetic parameters following a single oral administration of 100/25 mg levodopa/carbidopa administered 12 h after BIA 9-1067 (5 mg, 15 mg and 50 mg) or placebo on Day 11 (NCT02169414)
Timeframe: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose.

Interventionng.h/mL (Mean)
Placebo1861.3
BIA 9-1067 5 mg2332.3
BIA 9-1067 15 mg2736.8
BIA 9-1067 50 mg3182.6

[back to top]

AUC0-t - Area Under the Plasma Concentration-time Curve (AUC) of Levodopa From Time Zero to the Last Sampling Time at Which the Drug Concentration Was at or Above the Lower Limit of Quantification. (Levodopa/Benserazide)

Levodopa pharmacokinetic parameters following a single oral administration of 100/25 mg levodopa/benserazide administered 12 h after BIA 9-1067 (5 mg, 15 mg and 50 mg) or placebo on Day 18 (NCT02169414)
Timeframe: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose

Interventionng.h/mL (Mean)
Placebo2278.8
BIA 9-1067 5 mg2549.8
BIA 9-1067 15 mg3521.1
BIA 9-1067 50 mg3819.7

[back to top]

AUC0-t - Area Under the Plasma Concentration-time Curve (AUC) of Levodopa From Time Zero to the Last Sampling Time at Which the Drug Concentration Was at or Above the Lower Limit of Quantification. (Levodopa/Carbidopa)

AUC0-t - Area under the plasma concentration-time curve (AUC) of levodopa from time zero to the last sampling time following a single oral administration of 100/25 mg levodopa/carbidopa administered 12 h after BIA 9-1067 (5 mg, 15 mg and 50 mg) or placebo on Day 11 (NCT02169414)
Timeframe: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose.

Interventionng.h/mL (Mean)
Placebo1788.3
BIA 9-1067 5 mg2219.7
BIA 9-1067 15 mg2584.3
BIA 9-1067 50 mg2975.9

[back to top]

Cmax - Maximum Plasma Concentration of Levodopa (Levodopa/Benserazide )

Levodopa pharmacokinetic parameters following a single oral administration of 100/25 mg levodopa/benserazide administered 12 h after BIA 9-1067 (5 mg, 15 mg and 50 mg) or placebo on Day 18 (NCT02169414)
Timeframe: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose.

Interventionng/mL (Mean)
Placebo1770.3
BIA 9-1067 5 mg1379.8
BIA 9-1067 15 mg2118.3
BIA 9-1067 50 mg1813.7

[back to top]

Cmax - Maximum Plasma Concentration of Levodopa (Levodopa/Carbidopa)

Cmax - Maximum plasma concentration of levodopa following a single oral administration of 100/25 mg levodopa/carbidopa administered 12 h after BIA 9-1067 (5 mg, 15 mg and 50 mg) or placebo on Day 11 (NCT02169414)
Timeframe: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose.

Interventionng/mL (Mean)
Placebo966.6
BIA 9-1067 5 mg1026.8
BIA 9-1067 15 mg1097.9
BIA 9-1067 50 mg1019.7

[back to top]

Tmax - Time to Reach Maximum Plasma Concentration of Levodopa (Levodopa/Benserazide)

Levodopa pharmacokinetic parameters following a single oral administration of 100/25 mg levodopa/benserazide administered 12 h after BIA 9-1067 (5 mg, 15 mg and 50 mg) or placebo on Day 18 (NCT02169414)
Timeframe: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose.

Interventionhours (Mean)
Placebo0.89
BIA 9-1067 5 mg1.08
BIA 9-1067 15 mg0.7
BIA 9-1067 50 mg1.08

[back to top]

Tmax - Time to Reach Maximum Plasma Concentration of Levodopa (Levodopa/Carbidopa)

Tmax - Time to Reach maximum plasma concentration of levodopa following a single oral administration of 100/25 mg levodopa/carbidopa administered 12 h after BIA 9-1067 (5 mg, 15 mg and 50 mg) or placebo on Day 11 (NCT02169414)
Timeframe: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose.

Interventionhours (Median)
Placebo0.78
BIA 9-1067 5 mg1
BIA 9-1067 15 mg0.95
BIA 9-1067 50 mg1

[back to top]